225 / 400
MONDAY
TUESDAY
WEDNESDAY
THURSDAY
German language Session
Q&A Modul
SCIENTIFIC PROGRAMME
217
003
Measuring meaningful results in real-world
functioning of people suffering from schizophrenia
Silvana Galderisi, Italy
004
Future breakthroughs in the pharmacotherapy
of schizophrenia – duties of academic psychiatry
Peter Falkai, Germany
S-343
Symposium
08:15–09:45
|
Hall A4
TOPIC 17:
Psychotherapy
How to create progress within evidence-based
psychotherapy
Chairs:
Fritz Hohagen, Germany
Franz Caspar, Switzerland
001
Introduction to the topic
Mathias Berger, Germany
002
How does innovation fit into the framework
of evidence-based psychotherapy?
Pim Cuijpers, The Netherlands
003
Is individualized psychotherapy a motor of
innovation?
Franz Caspar, Switzerland
004
Metacognitive therapy: progress in psycho-
therapy grounded in cognitive psychology
Adrian Wells, United Kingdom
S-344
Symposium
08:15–09:45
|
Hall Helsinki 1
TOPIC 3:
Psychotic disorders
Rethinking psychosis: novel insights into pathophys-
iological mechanisms using a dimensional symptom
approach
Chairs:
Werner Strik, Switzerland
Thomas Dierks, Switzerland
001
Towards a neurobiologically informed psycho-
pathology of psychosis
Werner Strik, Switzerland
002
Persecutory delusions: advances in understand-
ing and treatment
Daniel Freeman, United Kingdom
003
Reconceptualising language in serious mental
illness using an RDoC framework
Kristin Nicodemus, United Kingdom
004
New insights into the aetiology and neurobiology
of motor symptoms in psychosis
Peter van Harten, The Netherlands
S-345
Symposium
08:15–09:45
|
Hall Helsinki 2
TOPIC 5:
Neurotic, stress-related and somatoform
disorders
Comprehensive update on the range of OCD treatments
Chairs:
Jens Kuhn, Germany
Ulrich Voderholzer, Germany
001
Health care research in OCD: new findings
from a survey in >400 patients
Ulrich Voderholzer, Germany
002
Internet-based CBT for OCD
Lina Lundström, Sweden
003
Advances of pharmacological treatments
Daniel Huys, Germany
004
Deep brain stimulation for OCD
Sina Kohl, Germany
S-346
Symposium
08:15–09:45
|
Hall Paris 1
TOPIC 14:
Neurobiology and genetics
Genetic variation and autoimmune influence on
corticolimbic circuitry in mood disorders: research
and clinical implications
›
WPA Section: Genetics in Psychiatry
Chairs:
Mark Frye, USA
Michael Bauer, Germany
001
Effects of genetic variation on corticolimbic
development in mood disorders
Hilary P. Blumberg, USA
002
Functional study of SNAP25 variation and risk
variant for bipolar disorder and schizophrenia
Stéphane Jamain, France
003
Effect of SLC1A2 variation on anterior cingulate
glutamate measurement in depression
Mark Frye, USA
004
Antibodies in autoimmune thyroiditis affect
glucose metabolism of anterior cingulate
Michael Bauer, Germany
Maximilian Pilhatsch